including rare familial forms of Parkinson disease. Our current research efforts include
The accumulation of aggregated alpha-synuclein within Lewy bodies and Lewy neurites is the defining feature of idiopathic Parkinson disease.
An alpha-synuclein imaging agent would improve the diagnosis of Parkinson disease and monitor the effectiveness of disease-modifying treatments.
including Pantothenate kinase-associated neurodegeneration and PLA2G6-associated neurodegeneration.
Investigating the ways in which mutations responsible for NBIA disorders affect the function of the enzymes encoded by the PANK2 and PLA2G6 genes.